AMENDMENT TO THE CLAIMS

The listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-93 (canceled).

94. (currently amended) The pharmaceutical composition comprising an ApoA-I agonist and a pharmaceutically acceptable carrier, excipient or diluent; wherein the ApoA-I agonist is in the form of an ApoA-I agonist-lipid complex, said complex comprising ~~an~~ the ApoA-I agonist and a lipid;

wherein the ApoA-I agonist comprises:

a 22 to 29-residue peptide or peptide analogue which forms an amphipathic α-helix in the presence of lipids and which comprises formula (I):

Z_1-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-X_{18}-X_{19}-X_{20}-X_{21}-X_{22}-X_{23}-Z_2

or a pharmaceutically acceptable salt thereof, wherein:

X_1 is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p);

X_2 is an aliphatic residue;

X_3 is Leu (L) or Phe (F);

X_4 is an acidic residue;

X_5 is Leu (L) or Phe (F);

X_6 is Leu (L) or Phe (F);

X_7 is a hydrophilic residue;

X_8 is an acidic or a basic residue;

X_9 is Leu (L) or Gly (G);

X_{10} is Leu (L), Trp (W) or Gly (G);

X_{11} is a hydrophilic residue;

X_{12} is a hydrophilic residue;

X_{13} is Gly (G) or an aliphatic residue;

X_{14} is Leu (L), Trp (W), Gly (G) or Nal;

X_{15} is a hydrophilic residue;

X_{16} is a hydrophobic residue;

Aliphatic AVLI

Acidic ED

Basic HRK

Polar NQST

Hydrophobic PIFVLWMAGY

Non-Polar LVIMGA

Hydrophilic TSHENQDKR

X_{17} is a hydrophobic residue;

X_{18} is Gln (Q), Asn (N) or a basic residue;

X_{19} is Gln (Q), Asn (N) or a basic residue;

X_{20} is a basic residue;

X_{21} is an aliphatic residue;

X_{22} is a basic residue;

X_{23} is absent or a basic residue;

Z_1 is H_2N- or RC(O)NR'-;

Z_2 is -C(O)NRR, -C(O)OR or -C(O)OH or a salt thereof;

each R is independently -H, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_5-C_{20}) aryl, (C_6-C_{26}) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one or more bonds between residues 1-7 are independently a substituted amide, an isostere of an amide or an amide mimetic;

each R' is independently -H, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_5-C_{20}) aryl, (C_6-C_{26}) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl; and

each "—" between residues X_1 through X_{23} independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic;

or

a N-terminally blocked form, a C-terminally blocked form, or an N- and C-terminally blocked form of formula (I).

95. (previously presented) The pharmaceutical composition of Claim 94 wherein X_7 of the ApoA-I agonist is a basic residue.

96. (previously presented) The pharmaceutical composition of Claim 94 wherein X_3, X_6, X_9 and X_{10} of the ApoA-I agonist are hydrophobic residues.

97. (previously presented) The pharmaceutical composition of Claim 94 wherein the ApoA-I agonist is a 22-23 residue peptide or peptide analogue according to formula (I).

98. (currently amended) The pharmaceutical composition of Claim 97 ~~comprising an ApoA-I agonist according to formula (I)~~ wherein:

the "—" between residues X_1 through X_{23} designates -C(O)NH-;

Z_1 is H_2N-; and

Z_2 is -C(O)OH or a salt thereof.

99. (currently amended) The pharmaceutical composition of Claim 98 ~~comprising an ApoA-I agonist according to formula (I)~~ wherein:

X_1 is Pro (P), Ala (A), Gly (G), Asn (N), Gln (Q), Asp (D) or D-Pro (p);

X_2 is Ala (A), Val (V) or Leu (L);

X_3 is Leu (L) or Phe (F);

X_4 is Asp (D) or Glu (E);

X_5 is Leu (L) or Phe (F);

X_6 is Leu (L) or Phe (F);

X_7 is Lys (K), Arg (R) or Orn;

X_8 is Asp (D) or Glu (E);

X_9 is Leu (L) or Gly (G);

X_{10} is Leu (L), Trp (W) or Gly (G);

X_{11} is Asn (N) or Gln (Q);

X_{12} is Glu (E) or Asp (D);

X_{13} is Gly (G), Leu (L) or Aib;

X_{14} is Leu (L), Nal, Trp (W) or Gly (G);

X_{15} is Asp (D) or Glu (E);

X_{16} is Ala (A), Nal, Trp (W), Leu (L), Phe (F) or Gly (G);

X_{17} is Gly (G), Leu (L) or Nal;

X_{18} is Gln (Q), Asn (N), Lys (K) or Orn;

X_{19} is Gln (Q), Asn (N), Lys (K) or Orn;

X_{20} is Lys (K) or Orn;

X_{21} is Leu (L);

X_{22} is Lys (K) or Orn; andX_{23} is absent or Lys (K).

100. (previously presented) The pharmaceutical composition of Claim 99 wherein X_{23} of the ApoA-I agonist is absent.

101

~~102~~. (Currently amended)) The pharmaceutical composition of Claim 94 ~~comprising an ApoA-I agonist according to formula (I)~~ wherein one of X_{18} or X_{19} is Gln (Q) or Asn (N) and the other of X_{18} or X_{19} is Lys (K) or Orn.

Claim 102 (canceled).

103. (currently amended) The pharmaceutical composition of Claim 94 ~~comprising an ApoA-I agonist~~ wherein the peptide or peptide analog is selected from the group consisting of:

peptide **1**	PVLDLFRELLNELLEZLKQKLK	(SEQ ID NO:1),
peptide **2**	GVLDLFRELLNELLEALKQKLKK	(SEQ ID NO:2),
peptide **3**	PVLDLFRELLNELLEWLKQKLK	(SEQ ID NO:3),
peptide **4**	PVLDLFRELLNELLEALKQKLK	(SEQ ID NO:4),
peptide **5**	pVLDLFRELLNELLEALKQKLKK	(SEQ ID NO:5),
peptide **6**	PVLDLFRELLNEXLEALKQKLK	(SEQ ID NO:6),
peptide **7**	PVLDLFKELLNELLEALKQKLK	(SEQ ID NO:7),
peptide **8**	PVLDLFRELLNEGLEALKQKLK	(SEQ ID NO:8),
peptide **9**	PVLDLFRELGNELLEALKQKLK	(SEQ ID NO:9),
peptide **10**	PVLDLFRELLNELLEAZKQKLK	(SEQ ID NO:10),
peptide **11**	PVLDLFKELLQELLEALKQKLK	(SEQ ID NO:11),
peptide **12**	PVLDLFRELLNELLEAGKQKLK	(SEQ ID NO:12),
peptide **13**	GVLDLFRELLNEGLEALKQKLK	(SEQ ID NO:13),
peptide **14**	PVLDLFRELLNELLEALOQOLO	(SEQ ID NO:14),
peptide **15**	PVLDLFRELWNELLEALKQKLK	(SEQ ID NO:15),
peptide **16**	PVLDLLRELLNELLEALKQKLK	(SEQ ID NO:16),
peptide **17**	PVLELFKELLQELLEALKQKLK	(SEQ ID NO:17),
peptide **18**	GVLDLFRELLNELLEALKQKLK	(SEQ ID NO:18),

peptide **19**	pVLDLFRELLNEGLEALKQKLK	(SEQ ID NO:19),
peptide **20**	PVLDLFREGLNELLEALKQKLK	(SEQ ID NO:20),
peptide **21**	pVLDLFRELLNELLEALKQKLK	(SEQ ID NO:21),
peptide **22**	PVLDLFRELLNELLEGLKQKLK	(SEQ ID NO:22),
peptide **23**	PLLELFKELLQELLEALKQKLK	(SEQ ID NO:23),
peptide **24**	PVLDLFRELLNELLEALQKKLK	(SEQ ID NO:24),
peptide **25**	PVLDFFRELLNEXLEALKQKLK	(SEQ ID NO:25),
peptide **26**	PVLDLFRELLNELLELLKQKLK	(SEQ ID NO:26),
peptide **27**	PVLDLFRELLNELZEALKQKLK	(SEQ ID NO:27),
peptide **28**	PVLDLFRELLNELWEALKQKLK	(SEQ ID NO:28),
peptide **29**	AVLDLFRELLNELLEALKQKLK	(SEQ ID NO:29),
peptide **123**	QVLDLFRELLNELLEALKQKLK	(SEQ ID NO:123),
peptide **124**	PVLDLFOELLNELLEALOQOLO	(SEQ ID NO:124),
peptide **125**	NVLDLFRELLNELLEALKQKLK	(SEQ ID NO:125),
peptide **126**	PVLDLFRELLNELGEALKQKLK	(SEQ ID NO:126),
peptide **127**	PVLDLFRELLNELLELLKQKLK	(SEQ ID NO:127),
peptide **128**	PVLDLFRELLNELLEFLKQKLK	(SEQ ID NO:128),
peptide **129**	PVLELFNDLLRELLEALQKKLK	(SEQ ID NO:129),
peptide **130**	PVLELFNDLLRELLEALKQKLK	(SEQ ID NO:130),
peptide **131**	PVLELFKELLNELLDALRQKLK	(SEQ ID NO: 131),
peptide **132**	PVLDLFRELLENLLEALQKKLK	(SEQ ID NO:132),
peptide **133**	PVLELFERLLEDLLQALNKKLK	(SEQ ID NO:133),
peptide **134**	PVLELFERLLEDLLKALNQKLK	(SEQ ID NO:134),
peptide **135**	DVLDLFRELLNELLEALKQKLK	(SEQ ID NO:135),
peptide **136**	PALELFKDLLQELLEALKQKLK	(SEQ ID NO:136),
peptide **137**	PVLDLFRELLNEGLEAZKQKLK	(SEQ ID NO:137),
peptide **138**	PVLDLFRELLNEGLEWLKQKLK	(SEQ ID NO:138),
peptide **139**	PVLDLFRELWNEGLEALKQKLK	(SEQ ID NO:139),
peptide **140**	PVLDLFRELLNEGLEALOQOLO	(SEQ ID NO:140),
peptide **141**	PVLDFFRELLNEGLEALKQKLK	(SEQ ID NO:141), and
peptide **142**	PVLELFRELLNEGLEALKQKLK	(SEQ ID NO:142),

and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof, wherein X is Aib; Z is Nal; and O is Orn.

104. (currently amended) The pharmaceutical composition of Claim 103 ~~comprising an~~ wherein the peptide or peptide analog ~~ApoA-I agonist that~~ is SEQ ID NO: 4.

Claims 105-109 (canceled).

110. (currently amended) The pharmaceutical composition of Claim 94 ~~comprising an ApoA-I agonist~~ wherein X_3 is Leu (L) or Phe (F), X_6 is Phe (F), X_9 is Leu (L) or Gly (G), and X_{10} is Leu (L), Trp (W) or Gly (G).

Claims 111-127 (canceled).